Serum tartrate-resistant acid phosphatase isoform 5a (TRACP5a) as a potential risk marker in cardiovascular disease

Anthony J. Janckila, Hseun Fu Lin, Yi Ying Wu, Chih Hung Ku, Shih Ping Yang, Wei Shiang Lin, Su Huei Lee, Lung T. Yam, Tsu Yi Chao

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objective: This study was undertaken to determine the association between serum tartrate-resistant acid phosphatase 5a (TRACP5a) and cardiovascular disease (CVD) risk. Methods: Four hundred patients were enrolled including, 291 asymptomatic subjects grouped by the number of traditional risk factors, 36 patients undergoing cardiac arteriography, 34 undergoing percutaneous cardiac intervention, and 39 with acute myocardial infarction. Serum was collected at baseline and, in arteriograpy and intervention groups, periodically for 1. week afterward. In addition to laboratory and clinical evaluation for risk assessment, serum TRACP5a, C-reactive protein (CRP) and interleukin-6 (IL-6) were determined. Results: All biomarkers rose with increasing CVD risk. Only serum TRACP5a, logCRP and cholesterol were elevated in symptomatic patients. Serum TRACP5a was higher in men and correlated with age, logCRP, logIL-6 and log-triglycerides, and in symptomatic patients, with the number of diseased coronary arteries. IL-6 and CRP showed acute phase responses, whereas TRACP5a did not change over 1. week after arteriography or intervention. After adjustment for all other variables and risk factors, TRACP5a and logCRP were the only biomarkers to associate with symptomatic disease. TRACP5a was more specific than CRP to predict myocardial infarction among all subjects. Conclusions: Serum TRACP5a is a macrophage-derived inflammation marker associated with CVD risk, and with coronary vessel disease and its severity and may be a useful marker for screening and assessment of CVD risk.

Original languageEnglish
Pages (from-to)963-969
Number of pages7
JournalClinica Chimica Acta
Volume412
Issue number11-12
DOIs
Publication statusPublished - May 12 2011

Fingerprint

Acid Phosphatase
Protein Isoforms
Cardiovascular Diseases
Serum
C-Reactive Protein
Biomarkers
Interleukin-6
Angiography
Myocardial Infarction
Acute-Phase Reaction
Tartrate-Resistant Acid Phosphatase
tartaric acid
Macrophages
Hypercholesterolemia
Risk assessment
Coronary Disease
Coronary Artery Disease
Coronary Vessels
Screening
Triglycerides

Keywords

  • Atherosclerosis
  • Cardiovascular risk
  • Inflammation
  • Macrophage
  • Myocardial infarction
  • Tartrate-resistant acid phosphatase

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Serum tartrate-resistant acid phosphatase isoform 5a (TRACP5a) as a potential risk marker in cardiovascular disease. / Janckila, Anthony J.; Lin, Hseun Fu; Wu, Yi Ying; Ku, Chih Hung; Yang, Shih Ping; Lin, Wei Shiang; Lee, Su Huei; Yam, Lung T.; Chao, Tsu Yi.

In: Clinica Chimica Acta, Vol. 412, No. 11-12, 12.05.2011, p. 963-969.

Research output: Contribution to journalArticle

Janckila, Anthony J. ; Lin, Hseun Fu ; Wu, Yi Ying ; Ku, Chih Hung ; Yang, Shih Ping ; Lin, Wei Shiang ; Lee, Su Huei ; Yam, Lung T. ; Chao, Tsu Yi. / Serum tartrate-resistant acid phosphatase isoform 5a (TRACP5a) as a potential risk marker in cardiovascular disease. In: Clinica Chimica Acta. 2011 ; Vol. 412, No. 11-12. pp. 963-969.
@article{c0fc98e2d4984d0dbf57c9603baafe12,
title = "Serum tartrate-resistant acid phosphatase isoform 5a (TRACP5a) as a potential risk marker in cardiovascular disease",
abstract = "Objective: This study was undertaken to determine the association between serum tartrate-resistant acid phosphatase 5a (TRACP5a) and cardiovascular disease (CVD) risk. Methods: Four hundred patients were enrolled including, 291 asymptomatic subjects grouped by the number of traditional risk factors, 36 patients undergoing cardiac arteriography, 34 undergoing percutaneous cardiac intervention, and 39 with acute myocardial infarction. Serum was collected at baseline and, in arteriograpy and intervention groups, periodically for 1. week afterward. In addition to laboratory and clinical evaluation for risk assessment, serum TRACP5a, C-reactive protein (CRP) and interleukin-6 (IL-6) were determined. Results: All biomarkers rose with increasing CVD risk. Only serum TRACP5a, logCRP and cholesterol were elevated in symptomatic patients. Serum TRACP5a was higher in men and correlated with age, logCRP, logIL-6 and log-triglycerides, and in symptomatic patients, with the number of diseased coronary arteries. IL-6 and CRP showed acute phase responses, whereas TRACP5a did not change over 1. week after arteriography or intervention. After adjustment for all other variables and risk factors, TRACP5a and logCRP were the only biomarkers to associate with symptomatic disease. TRACP5a was more specific than CRP to predict myocardial infarction among all subjects. Conclusions: Serum TRACP5a is a macrophage-derived inflammation marker associated with CVD risk, and with coronary vessel disease and its severity and may be a useful marker for screening and assessment of CVD risk.",
keywords = "Atherosclerosis, Cardiovascular risk, Inflammation, Macrophage, Myocardial infarction, Tartrate-resistant acid phosphatase",
author = "Janckila, {Anthony J.} and Lin, {Hseun Fu} and Wu, {Yi Ying} and Ku, {Chih Hung} and Yang, {Shih Ping} and Lin, {Wei Shiang} and Lee, {Su Huei} and Yam, {Lung T.} and Chao, {Tsu Yi}",
year = "2011",
month = "5",
day = "12",
doi = "10.1016/j.cca.2011.01.035",
language = "English",
volume = "412",
pages = "963--969",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",
number = "11-12",

}

TY - JOUR

T1 - Serum tartrate-resistant acid phosphatase isoform 5a (TRACP5a) as a potential risk marker in cardiovascular disease

AU - Janckila, Anthony J.

AU - Lin, Hseun Fu

AU - Wu, Yi Ying

AU - Ku, Chih Hung

AU - Yang, Shih Ping

AU - Lin, Wei Shiang

AU - Lee, Su Huei

AU - Yam, Lung T.

AU - Chao, Tsu Yi

PY - 2011/5/12

Y1 - 2011/5/12

N2 - Objective: This study was undertaken to determine the association between serum tartrate-resistant acid phosphatase 5a (TRACP5a) and cardiovascular disease (CVD) risk. Methods: Four hundred patients were enrolled including, 291 asymptomatic subjects grouped by the number of traditional risk factors, 36 patients undergoing cardiac arteriography, 34 undergoing percutaneous cardiac intervention, and 39 with acute myocardial infarction. Serum was collected at baseline and, in arteriograpy and intervention groups, periodically for 1. week afterward. In addition to laboratory and clinical evaluation for risk assessment, serum TRACP5a, C-reactive protein (CRP) and interleukin-6 (IL-6) were determined. Results: All biomarkers rose with increasing CVD risk. Only serum TRACP5a, logCRP and cholesterol were elevated in symptomatic patients. Serum TRACP5a was higher in men and correlated with age, logCRP, logIL-6 and log-triglycerides, and in symptomatic patients, with the number of diseased coronary arteries. IL-6 and CRP showed acute phase responses, whereas TRACP5a did not change over 1. week after arteriography or intervention. After adjustment for all other variables and risk factors, TRACP5a and logCRP were the only biomarkers to associate with symptomatic disease. TRACP5a was more specific than CRP to predict myocardial infarction among all subjects. Conclusions: Serum TRACP5a is a macrophage-derived inflammation marker associated with CVD risk, and with coronary vessel disease and its severity and may be a useful marker for screening and assessment of CVD risk.

AB - Objective: This study was undertaken to determine the association between serum tartrate-resistant acid phosphatase 5a (TRACP5a) and cardiovascular disease (CVD) risk. Methods: Four hundred patients were enrolled including, 291 asymptomatic subjects grouped by the number of traditional risk factors, 36 patients undergoing cardiac arteriography, 34 undergoing percutaneous cardiac intervention, and 39 with acute myocardial infarction. Serum was collected at baseline and, in arteriograpy and intervention groups, periodically for 1. week afterward. In addition to laboratory and clinical evaluation for risk assessment, serum TRACP5a, C-reactive protein (CRP) and interleukin-6 (IL-6) were determined. Results: All biomarkers rose with increasing CVD risk. Only serum TRACP5a, logCRP and cholesterol were elevated in symptomatic patients. Serum TRACP5a was higher in men and correlated with age, logCRP, logIL-6 and log-triglycerides, and in symptomatic patients, with the number of diseased coronary arteries. IL-6 and CRP showed acute phase responses, whereas TRACP5a did not change over 1. week after arteriography or intervention. After adjustment for all other variables and risk factors, TRACP5a and logCRP were the only biomarkers to associate with symptomatic disease. TRACP5a was more specific than CRP to predict myocardial infarction among all subjects. Conclusions: Serum TRACP5a is a macrophage-derived inflammation marker associated with CVD risk, and with coronary vessel disease and its severity and may be a useful marker for screening and assessment of CVD risk.

KW - Atherosclerosis

KW - Cardiovascular risk

KW - Inflammation

KW - Macrophage

KW - Myocardial infarction

KW - Tartrate-resistant acid phosphatase

UR - http://www.scopus.com/inward/record.url?scp=79954987830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954987830&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2011.01.035

DO - 10.1016/j.cca.2011.01.035

M3 - Article

VL - 412

SP - 963

EP - 969

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

IS - 11-12

ER -